{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-035948","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.007858+00:00","generated_at":"2026-06-04T08:23:10.059097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sutro Biopharma reports FY2023 revenue of $153.7M and $333.7M cash, runway into H2 2025","bullets":["Revenue $153.7M in FY2023 vs $67.8M in FY2022, driven by Vaxcyte option exercise and collaborations.","Cash and investments $333.7M plus Vaxcyte stock valued at $41.9M, providing runway into H2 2025.","Total operating expenses $243.0M; R&D $180.4M, G&A $62.6M; includes stock-based comp $24.9M, D&A $6.8M.","Jane Chung promoted to President and COO; enrollment in REFRαME-O1 for PROC ongoing, Part 1 expected complete H1 2024.","Vaxcyte paid $50M for manufacturing rights option, with additional $25M due within six months and up to $60M milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-035948","json":"https://secwatch.observer/filing/0000950170-24-035948.json","markdown":"https://secwatch.observer/filing/0000950170-24-035948.md","text":"https://secwatch.observer/filing/0000950170-24-035948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024035948/0000950170-24-035948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024035948/stro-20240325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:23:10.059097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e959339ffdfda421427a53f0ab48fdad6407caa6","claim":"SUTRO BIOPHARMA, INC. reported the year ended December 31, 2023 results: revenue $153.7 million.","evidence_excerpt":"stock on the last trading day of each reporting period, with any non-operating, unrealized gains and losses recorded in Sutro’s statements of operations. Revenue Revenue was $153.7 million for the year ended December 31, 2023, as compared to $67.8 million for the same period in 2022, with the 2023 amount related principally to the Vaxcyte manufacturing rights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024035948/0000950170-24-035948-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$153.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}